Clinical and Diagnostic Laboratory Immunology, November 1998, p. 745-748, Vol. 5, No. 6
1071-412X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
A Rapid Flow Cytometric Method to Explore Cellular Immunity
against Toxoplasma gondii in Humans
Sandrine
Kahi,1,2
Grégoire
J. N.
Cozon,1,3,*
Timothy
Greenland,4
Martine
Wallon,1,2
Françoise
Gay-Andrieu,1,2 and
François
Peyron1,2
Université Claude Bernard Lyon I, JE
1947,1
Unité
d'Immunologie,3
Laboratoire de
Parasitologie et Pathologie exotique,2
Hôpital de la Croix-Rousse, and Laboratoire
d'Immunologie et Biologie Pulmonaire, Hôpital Louis
Pradel,4 Lyon, France
Received 29 January 1998/Returned for modification 22 June
1998/Accepted 17 July 1998
 |
ABSTRACT |
To assess cell-mediated immunity to Toxoplasma gondii,
we evaluated the expression of the activation antigens CD69, CD71, and
CD25 on T lymphocytes by flow cytometry after specific in vitro
stimulation of whole blood from 127 T. gondii-positive and 63 T. gondii-negative patients. T lymphocytes from many
seropositive individuals did not express CD69 at 24 h after
T. gondii antigen stimulation, but CD71 and CD25 were
easily detectable on T cells from seropositive individuals 7 days after
specific activation. CD25 was mainly expressed by stimulated
CD4+ T cells, and its detection on total T cells was both a
sensitive (98%) and a specific (97%) indicator of prior T. gondii infection. These results make flow cytometric detection of
CD25 an excellent candidate for screening cell-mediated immunity to
T. gondii in vitro and an interesting tool for the
diagnosis of congenital infection.
 |
INTRODUCTION |
Infection with Toxoplasma
gondii is an important cause of morbidity and mortality in
neonates, persons infected with human immunodeficiency virus, and
persons with other defects in cell-mediated immunity (6, 9).
Protection against toxoplasmosis is mediated primarily by cellular
defenses. The key role of T lymphocytes in resistance against T. gondii was first demonstrated by Frenkel, who showed that hamsters
receiving spleen and lymphoid cells from T. gondii-infected
syngeneic donors were subsequently protected from an otherwise lethal
challeng (reviewed by Darcy and Santoro [6]). In
humans, T-cell proliferative responses after specific stimulation with
a T. gondii antigen(s) have been reported (1, 2,
16).
The standard way to quantify in vitro the cellular immune response to
an antigen, determination of cellular proliferation as measured by
incorporation of tritiated [3H]thymidine after contact
between cultured lymphocytes and the specific antigen (5),
is time-consuming and requires specialized radioactive equipment. An
alternative is to measure the expression of activation antigens, such
as CD69, CD25, CD71, or HLA-DR, on the lymphocyte membrane. These
molecules are absent from, or present at very low levels on, the
surfaces of resting cells but are induced following contact with
specific antigen. CD69 expression peaks at 24 h after in vitro
stimulation of T cells (12), while maximal CD25
(interleukin-2 receptor) or CD71 (transferrin receptor) expression requires 4 to 8 days of culture with mitogen or antigen (3). The percentage of T lymphocytes expressing these membrane antigens following stimulation of mononuclear cells or whole blood with specific
antigen can easily be determined by flow cytometry (3, 11,
12). Using this simple method, we have evaluated the T-cell responses of individuals with and without specific antibodies to
T. gondii and determined that the CD25 response at 7 days is an accurate indicator of prior infection.
 |
MATERIALS AND METHODS |
Subjects.
Blood collected from 190 individuals by using
Vacutainer tubes (Becton Dickinson, Meylan, France) containing lithium
heparin anticoagulant was sent to the Laboratoire de Parasitologie for diagnosis or follow-up of toxoplasmosis. T. gondii
antibodies were evaluated by using a commercial enzyme-linked
immunosorbent assay (Enzygnost; Behring, Rueil Malmaison, France).
Specific-immunoglobulin G (IgG) titers of <25 U/ml or IgM titers of
<6 (arbitrary units) were considered negative. By these criteria, 127 individuals showed serologic evidence of prior infection with T. gondii (congenital toxoplasmosis, n = 84, age
[mean ± standard deviation] = 6 ± 4 years; chronic
infection, n = 24, age = 35 ± 10 years;
toxoplasmic retinochoroiditis, n = 12, age = 18 ± 6 years; and acute infection, n = 7, age = 29 ± 4 years). The 63 others were T. gondii
negative (age = 29 ± 5 years).
In vitro activation.
Samples of 50 µl of whole blood were
placed in 45- by 8.8-mm tubes (Micronic Systems, Lelystad, The
Netherlands), and duplicate specimens were treated with an equal volume
of soluble T. gondii antigen (final concentration, 6 µg/ml), negative-control culture supernatant, or phytohemagglutinin
(10 µg/ml; Sigma, St. Quentin Fallavier, France) as a positive
control. Soluble T. gondii antigen was prepared by infection
of murine WEHI 164 cells (ATCC CRL 1751), at three tachyzoites/cell,
with T. gondii strain RH from the peritoneal cavities of
24-h-infected OF1 mice (Iffa Credo, Saint Germain sur l'Arbresle,
France). At 2 days the tachyzoites were harvested, washed, adjusted to
106/ml in phosphate-buffered saline (Biomérieux,
Marcy l'Etoile, France), and disrupted by five freeze-thaw cycles. The
suspension was clarified by centrifugation at 2,500 × g for 15 min and passaged through a 0.2-µm-pore-size
filter. Negative-control culture supernatant was collected from
uninfected WEHI 164 cells. Blood cells were collected after 24 h
of culture at 37°C in the presence of antigen for determination of
CD69 expression and after 7 days for determination of CD25 or CD71
expression. The 7-day cultures were supplemented at 24 h with 500 µl of RPMI 1640 medium containing 1% L-glutamine, penicillin (10,000 U/ml), streptomycin (10 mg/ml), and amphotericin B
(25 mg/ml; Sigma).
Membrane staining and flow cytometry.
Excess medium was
decanted from the cell suspensions, and erythrocytes were lysed with
(per liter) 155 mmol of NH4Cl, 10 mmol of
KHCO3, and 0.1 mmol of EDTA. The leukocytes were recovered by centrifugation, and the pellets were stained with a combination of
three specific monoclonal antibodies labelled with distinguishable fluorochromes for 15 min in the dark at 4°C. For CD69 detection, a
commercial preparation (Becton Dickinson, Pont de Claix, France) consisting of antibody to CD3 (Leu 4) conjugated with peridininin chlorophyll protein, anti-CD4 (Leu 3) conjugated with fluorescein isothiocyanate (FITC), and anti-CD69 (Leu 23) conjugated with phycoerythrin (PE) was used. A combination of FITC-conjugated antibodies to either CD25 or CD71 (Dako, Trappes, France) with PE-anti-CD4 (Sigma) and cyanin 5-phycoerythrin (Cy5PE)-conjugated anti-CD3 (Dako) was used to estimate CD25 and CD71 expression. The
cells were then washed and resuspended in phosphate-buffered saline-0.1% bovine serum albumin-5 mM EDTA and analyzed the same day
by three-color analysis with a FACScan flow cytometer (Becton Dickinson). Lysis II software was used in acquisition, with
fluorescence triggering in the f13 channel to gate on CD3+
lymphocyte populations. Data were then displayed as two-color dot plots
(fl1 and fl2) on the fl3 positive cells to measure the proportion of
activated lymphocyte subsets that expressed CD25 or CD71 (Fig.
1). Similar results were obtained for
CD69 expression after staining with specific antibodies (data not
shown). Specific positivity of CD3+ or CD4+
cells expressing activation antigens was estimated by subtracting the
values obtained for negative-control culture supernatant cells from
those obtained for cells treated with soluble T. gondii
antigen.

View larger version (36K):
[in this window]
[in a new window]
|
FIG. 1.
Flow cytometric analysis of CD25 and CD71 expression on
T. gondii-stimulated CD4+ and
CD4 T lymphocytes. Whole blood from a positive donor was
incubated for 7 days with soluble T. gondii antigen
(bottom row) or with negative-control culture supernatant (top row).
Cells were stained, as described in Materials and Methods, with a
combination of Cy5PE-conjugated anti-CD3, PE-conjugated anti-CD4, and
FITC-conjugated anti-CD25 (second column) or anti-CD71 (third column)
antibodies. Resting and activated CD3+ cells were gated on
R1 (first column).
|
|
Statistical tools.
Differences in the percentages of cells
expressing the three activation antigens were tested for significance
with the Mann-Whitney U test and Student's t test.
 |
RESULTS |
Blood samples from 20 subjects (10 chronically infected and
seropositive and 10 seronegative for T. gondii-specific
antibodies) were compared for CD69, CD25, and CD71 expression on
CD3+ lymphocytes after stimulation with soluble T. gondii antigen. Lymphocytes from all patients strongly
expressed CD69, CD25, and CD71 after stimulation with
phytohemagglutinin (data not shown). Supernatants of uninfected WEHI
164 cells used as negative controls never induced activation (data not
shown). Figure 2 shows that CD25 and CD71
were expressed, respectively, by 40.60% ± 13.21% and 32.63% ± 18.65% of CD3+ lymphocytes from T. gondii-positive individuals while CD69 was induced on only 1.82% ± 2.05% of cells (P < 0.0001 in each case). None of
these antigens were expressed by stimulated CD3+
lymphocytes from T. gondii-negative individuals. Since CD25
was specifically expressed on a consistently high percentage of
CD3+ cells from positive donors, we chose this activation
antigen as the indicator of a T. gondii-specific cellular
response in a large series of donors.

View larger version (12K):
[in this window]
[in a new window]
|
FIG. 2.
Percentages of CD3+ lymphocytes expressing
CD69, CD71, and CD25 above control levels after in vitro stimulation
with soluble T. gondii antigen in whole blood from 10 T. gondii-positive (T.g.+) and 10 T. gondii-negative (T.g. ) individuals. Stimulation and
staining were performed as described in Materials and Methods. Each
symbol represents one individual. Statistical analysis (Mann-Whitney U
test) showed significantly higher percentages of CD3+
CD25+ and CD3+ CD71+ cells than of
CD3+ CD69+ cells in T.g.+ individuals
(P < 0.0001 in each case).
|
|
Intra-assay reproducibility was first determined with 10 replicate
whole-blood samples from a single seropositive donor, separately stimulated with soluble T. gondii antigen. The optimal
incubation time was determined from a kinetic curve (data not shown),
and the percentages of CD3+ or CD3+
CD4+ cells expressing significant levels of CD25 fell
between 55.5 and 62.6%, with coefficients of variation of 4.4 and
4.5%, respectively. Ten identical replicate samples stimulated with
control supernatant produced only a small number (0.9 to 1.5%) of
CD25-expressing cells.
Blood samples from 190 individuals were evaluated for expression of
CD25 after stimulation with soluble T. gondii antigen (Fig. 3). A significantly greater
percentage of lymphocytes from T. gondii-positive than from
T. gondii-negative individuals expressed CD25 after specific
stimulation (3.25 to 83.15% versus 0 to 15.95%; P < 0.0001). Two of 63 seronegative patients showed abnormally high
cellular responses to antigen, while 3 of 127 seropositive individuals
showed only weak specific stimulation of CD25 expression. In this
population, if we adopt as the threshold a value of 3 standard
deviations above the mean percentage of CD3+ lymphocytes
from negative donors expressing CD25 after specific stimulation
(10.1%), we obtain a specificity of 97% (95% confidence interval = 92 to 100) and a sensitivity of 98% (95% confidence interval = 95 to 100). CD4+ cells were always present
in the T-cell population expressing CD25 after specific stimulation,
while only 31% of positive donors had CD4
T cells which
could be induced to express CD25. The ratio of CD4+ cells
to CD4
cells increased after stimulation of responders by
T. gondii antigen only when the CD4+ cells
and not the CD4
cells showed a positive response.

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 3.
Percentages of CD3+ lymphocytes expressing
CD25 above control levels after in vitro stimulation with soluble
T. gondii antigen in whole blood of 190 individuals
(127 positive for T. gondii-specific IgG antibodies
[T.g.+] and 63 negative [T.g. ]). Stimulation and
staining were performed as described in Materials and Methods. Boxes
represent values between 25th and 75th percentiles and medians; bars
indicate 10th and 90th percentiles. Circles outside the bars are extra
values. The horizontal bar shows mean percentages + 3 standard
deviations. Statistical analysis (Student's t test) showed
significantly higher percentages of CD3+ CD25+
cells in T.g.+ than in T.g. individuals (P < 0.0001).
|
|
 |
DISCUSSION |
We describe a convenient method for evaluating cellular immune
responses in toxoplasmosis patients which requires no manipulation of
radioactive materials. The expression of activation antigens by T
lymphocytes after specific stimulation with an antigen to which an
individual has had prior exposure can be readily measured by flow
cytometry and can be induced in a small sample of whole blood without
separation of leukocytes. We evaluated three such antigens. CD69
expression occurs rapidly (24 h) on antigen-reactive cells, but the
small number (<2%) of such cells precluded accurate identification of
positive individuals. The number of CD69-positive cells did not
increase over 6 days of culture (data not shown) because CD69 is a very
early activation marker and its expression decreases rapidly
(4). CD69 expression is also unreliable in evaluating
cellular responses to tetanus toxoid (12). CD25 and CD71
were regularly induced on a much larger percentage of T lymphocytes from T. gondii-seropositive than T. gondii-seronegative subjects. These antigens also show an
amplified expression in response to tetanus toxoid or influenza virus
antigens (3). Both appear suitable for the evaluation of a
cellular response, but the smaller range of dispersion of the
percentage of cells expressing CD25 led us to choose this marker for
further evaluation.
The test proved to correlate well with serological status, and samples
from seronegative individuals usually showed no stimulation by our
antigen preparation, in agreement with a previous report (14). Less pure antigen preparations are liable to evoke
CD25 expression on lymphocytes from T. gondii-seronegative individuals (data not shown). Nevertheless, 2 of 63 negative individuals expressed CD25 on an anomalously high
percentage of T cells after specific stimulation. This could
reflect a superantigen effect (7) or possibly
cross-reactivity to a related parasite. The three anomalously low
responses in seropositive individuals all occurred in
congenitally infected children aged 1 year or older. Absence of
stimulation of lymphocytes by T. gondii antigen,
measured by [3H]thymidine incorporation, has been
described, both for acute acquired T. gondii infection
(1, 8) and for congenitally infected children (10, 15,
16). In our study, most positive subjects had congenital
infection. The small number of low measurements may reflect the fact
that CD25 expression does not depend on cellular proliferation
(3).
Detection of CD25 expression by flow cytometry is as specific as
measurement of [3H]thymidine incorporation for detecting
lymphocyte responses to T. gondii (1, 15,
16) and provides more information about the cellular immune
response. In particular, T-lymphocyte subsets implicated in activation
can be easily assessed and compared individually for their responses to
stimuli. Unlike in studies with staphylococcal enterotoxin B
(11), tetanus toxoid, and influenza virus (3), where stimulation induced almost identical percentages of
CD4+ and CD4
activated T cells CD25 was
predominantly detected on CD4+ cells. This agrees with
recent studies of humans revealing that T. gondii-infected antigen-presenting cells elicited stronger CD4-mediated than CD8-mediated cell proliferation and generated CD4+ cytotoxic T lymphocytes more readily than
CD8+ cytotoxic T lymphocytes (2, 13).
The test we describe is simple, uses cytometry apparatus readily
available in many hospital laboratories, and requires no specific
radioactive equipment. Even if the incubation periods are long (7 days), the assay itself can be performed directly on whole blood in a
few short steps. CD25 can be detected earlier, but maximal
expression is required for clear-cut differentiation between
positive and negative patients. Only 300 µl of whole blood is needed,
which is an advantage in taking samples from children, with whom
sampling is always delicate. The technique allows exploration of
cell-mediated immunity and could be adapted to other microbial agents.
We are attempting detection of CD25 expression in whole blood from
newborn children for early diagnosis of congenital infection.
 |
ACKNOWLEDGMENTS |
This work was supported by grants (UCBL JE 1947).
We thank J. Ferrandiz and C. Bernardoux for their helpful technical
assistance, as well as M. Alkurdi.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Unité
d'Immunologie, Hôpital de la Croix-Rousse, 93 Grande Rue de la
Croix-Rousse, 69317 Lyon cedex 04, France. Phone: (33) 4 72 07 19 52. Fax: (33) 4 72 07 18 48. E-mail:
gcozon{at}rockefeller.univ-lyon1.fr.
 |
REFERENCES |
| 1.
|
Anderson, S. E.,
J. L. Krahenbuhl, and J. S. Remington.
1979.
Longitudinal studies of lymphocyte responses to Toxoplasma antigens in humans infected with T. gondii.
J. Clin. Lab. Immunol.
2:293-297[Medline].
|
| 2.
|
Canessa, A.,
V. Pistoia,
A. Merli,
G. Melioli,
A. Terragna, and M. Ferranini.
1988.
An in vitro model of toxoplasma infection in man. Interaction between CD4+ monoclonal T cells and macrophages results in killing of trophozoites.
J. Immunol.
140:3580-3588[Abstract].
|
| 3.
|
Caruso, A.,
S. Licenziati,
M. Corulli,
A. D. Canaris,
M. A. De Francesco,
S. Fiorentini,
L. Peroni,
F. Fallacara,
F. Dima,
A. Balsari, and A. Turano.
1997.
Flow cytometric analysis of activation markers on stimulated T cells and their correlation with cell proliferation.
Cytometry
27:71-76[Medline].
|
| 4.
|
Cebrian, M.,
E. Yagüe,
M. Rincon,
M. Lopez-Botet,
M. O. de Landazuri, and F. Sanchez-Madrid.
1988.
Triggering of T cell proliferation through AIM, an activation inducer molecule expressed on activated human lymphocytes.
J. Exp. Med.
168:1621-1637[Abstract/Free Full Text].
|
| 5.
|
Corradin, G.,
H. M. Etlinger, and J. M. Chiller.
1977.
Lymphocyte specific T-cell dependent proliferative response with lymph node cells from primed mice.
J. Immunol.
119:1048-1053[Abstract/Free Full Text].
|
| 6.
|
Darcy, F., and F. Santoro.
1994.
Toxoplasmosis, p. 163-201.
In
F. Kierszenbaum (ed.), Parasitic infections and the immune system. Academic Press Inc., San Diego, Calif.
|
| 7.
|
Denkers, E. Y.,
P. Caspar, and A. Sher.
1994.
Toxoplasma gondii possesses a superantigen activity that selectively expands murine T cell receptor V 5-bearing CD8+ lymphocytes.
J. Exp. Med.
180:985-994[Abstract/Free Full Text].
|
| 8.
|
Johnson, W. D., Jr.
1981.
Chronological development of cellular immunity in human toxoplasmosis.
Infect. Immun.
33:948-949[Abstract/Free Full Text].
|
| 9.
|
Luft, B. J., and J. S. Remington.
1992.
Toxoplasmic encephalitis in AIDS.
Clin. Infect. Dis.
15:211-219[Medline].
|
| 10.
|
MacLeod, R.,
M. O. Beem, and R. G. Estes.
1985.
Lymphocyte anergy specific to Toxoplasma gondii antigens in a baby with congenital toxoplasmosis.
J. Clin. Lab. Immunol.
17:149-153[Medline].
|
| 11.
|
Maino, V. C.,
M. A. Suni, and J. J. Ruitenberg.
1995.
Rapid flow cytometric method for measuring lymphocyte subset activation.
Cytometry
20:127-133[Medline].
|
| 12.
|
Mardiney, M., III,
M. R. Brown, and T. A. Fleisher.
1996.
Measurement of T-cell CD69 expression: a rapid and efficient means to assess mitogen- or antigen-induced proliferative capacity in normals.
Cytometry
26:305-310[Medline].
|
| 13.
|
Purner, M. B.,
R. L. Berens,
P. B. Nash,
A. van Linden,
E. Ross,
C. Kruse,
E. C. Krug, and T. J. Curiel.
1996.
CD4-mediated and CD8-mediated cytotoxic and proliferative immune responses to Toxoplasma gondii in seropositive humans.
Infect. Immun.
64:4330-4338[Abstract].
|
| 14.
|
Purner, M. B.,
E. C. Krug,
P. Nash,
D. R. Cook,
R. L. Berens, and T. J. Curiel.
1995.
Cross-reactivity of human Toxoplasma-specific T cells: implications for development of a potential immunotherapeutic or vaccine.
J. Infect. Dis.
171:984-991[Medline].
|
| 15.
|
Stray-Pedersen, B.
1980.
Infants potentially at risk for congenital toxoplasmosis.
Am. J. Dis. Child.
134:638-642[Abstract].
|
| 16.
|
Wilson, C. B.,
G. Desmonts,
J. Couvreur, and J. S. Remington.
1983.
Lymphocyte transformation in the diagnosis of congenital toxoplasma infection.
N. Engl. J. Med.
302:785-788[Medline].
|
Clinical and Diagnostic Laboratory Immunology, November 1998, p. 745-748, Vol. 5, No. 6
1071-412X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.